Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

By R. C. Coombes, L. Kilburn, C. Snowdon, R. Paridaens, R. Coleman, Stephen E. Jones, J. Jassem, C. V. D. Velde, T. Delozier, I. Álvarez and 24 more. The Lancet, 2007

866 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/30157f579e9d676dc70337ae06dd6706cc55c757

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Senkus
2. S. Kyriakides
3. F. Penault-Llorca
4. S. Ohno
5. F. Cardoso
6. W. Wood
7. P. Poortmans
8. E. Rutgers

Citations in the corpus

• Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, background): “Clearly the availability of third generation aromatase inhibitors (AIs) [24, 84–88] has added substantially to the available treatment choice after a quarter century of successful use of tamoxifen.”
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “In postmenopausal patients AIs can be used upfront [3, 20] for 5 years, with one trial [20] reporting a modest survival benefit as compared with tamoxifen; or AIs can be prescribed sequentially after 2–3 years of tamoxifen [I, A] [21].”